GW Pharmaceuticals

GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

GW Pharmaceuticals: Recommendations and Market Capitalization

The above chart compares changes in analysts’ recommendations since January 2018.

Analyst recommendations

Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months. They’ve set a 12-month target price of $175 compared to its closing price of $164.07 on October 3.

There are nine analysts tracking GW Pharmaceuticals stock. Two of them have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “strong sell.” The consensus rating for GW Pharmaceuticals is 2.11, which represents a “strong buy” for long-term growth investors and value investors.

Market capitalization

The market capitalization for GW Pharmaceuticals is ~$4.6 billion as of October 4.

The total number of GW Pharmaceuticals shares outstanding are ~27.77 million. Of those, free float shares are ~27.76 million, which is 99.97% of the total outstanding shares. Institutions hold ~79.1% of the total shares, while strategic entities own ~0.03%.

The top ten shareholders hold 45.6% of GW Pharmaceuticals shares. Capital Research Global Investors is the largest shareholder with 3.38 million shares. That’s 12.2% of the company’s total shares.

Capital World Investors holds 2.18 million shares, which is 7.8% of the total shares. Scopia Capital Management holds 2.04 million shares, which is 7.3% of the total shares.

The Invesco BLDRS Developed Markets 100 ADR ETF (ADRD) has 0.1% of its total investments in GW Pharmaceuticals (GWPH), 0.5% in Teva Pharmaceutical Industries (TEVA), 1.3% in Shire (SHPG), and 2% in Novo Nordisk (NVO).

Latest articles

On Tuesday, Tesla (TSLA) cut the prices of its vehicles to standardize its global car line-up, according to Reuters.

Yesterday, PayPal (PYPL) announced that it would expand Xoom, which is its international money transfer service, to 32 markets in Europe.

Visa stock has risen about 37% and has outperformed the S&P 500 Index so far in 2019.

16 Jul

What to Expect from Skechers’s Q2 Results

WRITTEN BY Sharon Bailey

Skechers (SKX) is set to declare its results for the second quarter after the markets close on July 18. Here's what you should know.

On Tuesday, Canadian Pacific Railway (CP) reported strong second-quarter earnings. The company's top and bottom lines touched a record mark.

16 Jul

What to Expect from Crown Castle's Q2 Results

WRITTEN BY Sushree Mohanty

Crown Castle International (CCI) is scheduled to announce its second-quarter earnings results on Wednesday after the market closes.